LBTSF News and Press, Almirall Sa Ord From 10/13/23

These primary data of the ADvantage study were presented today at EADV Congress A total of 18 lebrikizumab abstracts were disclosed at EADV, including new data on the depth of response at Week 52 and long-term clinically meaningful response Lebrikizumab also demonstrated improveme...

Interim data from the POSITIVE study, presented at the EADV, revealed that tildrakizumab not only significantly improved patients’ wellbeing after 16 weeks, which was maintained up to week 28 1 but also had a positive impact on the wellbeing of their relatives after 28 weeks 2 ...

2023-07-24 14:07:11 ET Almirall, S.A. (LBTSF) Q2 2023 Earnings Conference Call July 24, 2023 4:00 AM ET Company Participants Pablo Divasson - Director of Investor Relations and Corporate Communications Carlos Gallardo - Chairman and Chief Executive Officer Karl Z...

The European dermatology business remains the key driver of Almirall’s growth with a robust 15% year-on-year increase, based on solid business momentum generated by our key growth and recently launched products. Total EBITDA amounted to €101.3 MM as the sales growth was offset by lo...

At the 25th World Congress of Dermatology Tildrakizumab also significantly improved skin symptoms and quality of life in patients with moderate to severe plaque psoriasis after 28 weeks in a real-world setting and with a safety profile consistent with randomized phase III clinical tri...

The miniseries follows the life of an enigmatic fashion designer with psoriasis and her journey to cope with the effects of the disease on her daily life Psoriasis has a high impact beyond the skin, seriously affecting the mental and emotional health of those living with the disease. 1,...

Almirall S.A. (ALM) (the “ Company ”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital increase announced yesterday evening (the “ Capital Increase ”) fo...

THE INFORMATION CONTAINED HEREIN MUST NOT BE DISCLOSED, PUBLISHED OR DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION, PUBLICATION OR DISSEMINATION WOULD BE UNLAWFUL. THIS COMM...

2023-05-08 13:53:06 ET Almirall, S.A. (LBTSF) Q1 2023 Results Conference Call May 8, 2023 04:00 AM ET Company Participants Pablo Divasson - Director of IR and Corporate Communications Carlos Gallardo - Chairman & CEO Mike McClellan - CFO Karl Ziegelbauer ...

Almirall's Net Sales reach € 232MM and increase by 6%, boosted by a solid European dermatology business The European dermatology business achieved excellent performance, with Net Sales increasing by 11.4% year-on-year, driven by solid business momentum from key products and positiv...